Thyrocare, Lal Pathlabs: Diagnostic stocks trade weak. Should you worry?

Given the weakness seen on Monday, should you be worried regarding stocks from this sector? Here is how they look on the charts

Stocks of diagnostic firms such as Dr. Lal Pathlabs and Metropolis Healthcare slipped in trade today. This seems to be a rub-off effect of Thyrocare Technologies that lost ground after Docon Technologies, along with API Holdings, the parent company of unicorn PharmEasy, an online medical platform, said it will acquire 66.1 per cent equity stake in diagnostic chain firm for Rs 4,546 crore.

This would be the first ever acquisition of a listed company, by an Indian unicorn, the companies said in a joint statement. "It is the third big-ticket transaction involving an e-pharmacy company," they said. READ ABOUT